AnalystBook Research · Company Intelligence

AMGEN INC

AMGNNasdaq

Built from AMGEN INC's own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data

Amgen: Revenue grew 10.0% to $36.751B from $33.424B. Net income grew 88.5% to $7.711B from $4.09B. Free cash flow declined 22.1% to $8.1B from $10.394B. Operating margin expanded 300 bps to 24.71%. Amgen's annual comparison also shows free cash flow declined despite revenue growth; capital spending grew faster than revenue; the balance-sheet screen falls in the distress range and requires business-model context.

The read at a glance✓ Audited against SEC data
  • Growth — Revenue grew 10.0%OK
  • Profitability — Net income grew 88.5% to $7.711B from $4.09BOK
  • Cash flow — Free cash flow declined 22.1% to $8.1B from $10.394BWatch
  • Margins — Operating margin expanded 300 bps to 24.71%OK
  • Accounting — Distress-range screen needs contextWatch
  • Insiders — 0 purchases and 7 salesNote

Business

Amgen develops and markets biologic and small-molecule medicines.

Where the revenue comes from

Fiscal 2025, as AMGEN INC reports it. History and quarterly detail are in the app.

  • Product sales$35.1B
  • Other products$7.3B
  • Prolia$4.4B
  • Repatha$3.0B
  • Otezla$2.3B

Leadership changes

From AMGEN INC's own filings, the day they're filed.

  • Peter H. Griffith · Chief Financial Officer · departureeff. 2026-08-31
  • Thomas Dittrich · Chief Financial Officer · departureeff. 2026-07-01
  • Peter H. Griffith · Chief Financial Officer · departureeff. 2026-06-01

Latest filings

  • 10-Q · Quarterly report2026-08-05
  • 8-K · Company announcement2026-08-04
  • 8-K · Company announcement2026-07-31
  • 8-K · Company announcement2026-05-20
  • 8-K · Company announcement2026-05-19
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about AMGEN INC, every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

See the full AMGN record — start free

14-day free trial, no credit card. For research purposes only; not investment advice.